Novel approaches to treating mental health conditions
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders. Enveric is committed to developing novel treatments to transform the lives of patients living with mental illness. We are pursuing new pathways and targeting impaired neural circuitry with the goal of improving brain health. Our mission is to pioneer new and innovative solutions with the potential to have profound effects on patients and their families, and to deliver life-changing medicines for diseases affecting the brain. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada.
Our Approach to New Drug Development
Enveric has created a robust Intellectual Property (IP) portfolio of New Chemical Entities (NCEs), known as The Psybrary™, through its unique discovery and development platform and collaborations with leading global institutions.
To date, Enveric has synthesized hundreds of proprietary molecules, and by utilizing its artificial intelligence platform, PsyAI™, Enveric has been able to optimize its discovery efforts and narrow down the potential compound variations in order to select the best candidate molecules for specific mental health indications or physical ailments.
A New Approach to Solving Mental Health Challenges
Enveric is dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.